Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/15/2021 06/16/2021 06/17/2021 06/18/2021 06/21/2021 Date
189.64(c) 190.14(c) 199.64(c) 197.34(c) 198.195 Last
258 084 228 959 509 040 1 123 875 94 531 Volume
-2.82% +0.26% +5.00% -1.15% +0.43% Change
More quotes
Financials (USD)
Sales 2021 585 M - -
Net income 2021 97,5 M - -
Net cash position 2021 596 M - -
P/E ratio 2021 116x
Yield 2021 -
Sales 2022 683 M - -
Net income 2022 112 M - -
Net cash position 2022 786 M - -
P/E ratio 2022 102x
Yield 2022 -
Capitalization 10 835 M 10 835 M -
EV / Sales 2021 17,5x
EV / Sales 2022 14,7x
Nbr of Employees -
Free-Float 93,0%
More Financials
Company
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used... 
More about the company
Ratings of Repligen Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about REPLIGEN CORPORATION
05/25Repligen Corporation to Present at Upcoming Investor Conferences
GL
05/21REPLIGENá : Continued Level of Significant Insider Selling at Repligen (RGEN)
MT
05/20INSIDER TRENDS : Insider Sales Continue 90-Day Trend at Repligen
MT
05/19REPLIGEN CORPá : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/18INSIDER TRENDS : Insider Sale at Repligen Slowing 90-Days of Buying
MT
05/11REPLIGENá : 2020 Annual Report (PDF)
PU
05/05REPLIGENá : HC Wainwright Adjusts Repligen's Price Target to $240 From $225, Mai..
MT
05/04REPLIGENá : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
05/04REPLIGENá : Posts Rise in Q1 Adjusted Profit, Revenue; Amends 2021 Forecasts
MT
05/04REPLIGENá : Reported revenue was $142.8 million for the quarter, representing ye..
PU
05/04REPLIGEN CORPá : Results of Operations and Financial Condition, Financial Statem..
AQ
05/04REPLIGEN : Q1 Earnings Snapshot
AQ
05/04REPLIGENá : Earnings Flash (RGEN) REPLIGEN CORPORATION Posts Q1 Revenue $142.8M,..
MT
05/04REPLIGENá : Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q1 EPS $0.68, vs...
MT
05/04Repligen Reports First Quarter 2021 Financial Resultsáand Updates Full Year 2..
GL
More news
News in other languages on REPLIGEN CORPORATION

- No features available -

More news
Analyst Recommendations on REPLIGEN CORPORATION
More recommendations
Stock Trading Strategies
REPLIGEN CORPORATION - 2020
Good timing to anticipate a continuation of the trend
BUY
More Stock Trading Analysis
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 240,25 $
Last Close Price 197,34 $
Spread / Highest target 27,2%
Spread / Average Target 21,7%
Spread / Lowest Target 1,35%
EPS Revisions
Managers and Directors
NameTitle
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen T. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Senior Vice President-Global Operations & IT
Sector and Competitors
1st jan.Capitalization (M$)
REPLIGEN CORPORATION2.98%10 835
ABBOTT LABORATORIES0.77%196 037
MEDTRONIC PLC5.20%165 794
BECTON, DICKINSON AND COMPANY-3.87%69 953
HOYA CORPORATION1.26%48 451
ALIGN TECHNOLOGY, INC.12.59%47 612